Psychopharmacotherapy for Depressive Patients
ConditionMajor Depressive Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-65
SponsorChonnam National University Hospital
About this trial
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.
Eligibility criteria
Qualifiers
19 to 65 years
Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder by study psychiatrists
Score≥17 on Hamilton Depression Rating Scale-17
With ability to understand the objective of the study and sign informed consent
Disqualifiers
Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders
current major depressive disorder with psychotic features
History of organic psychosis, epilepsy, or seizure disorder
Current anorexia nervosa or obsessive compulsive disorder
Trial design
Treatments tested in this trial
- stepwise pharmacotherapy
- antidepressant monotherapy group
Treatment groups
400 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov